Timothy B.  Lowinger net worth and biography

Timothy Lowinger Biography and Net Worth

Since joining Mersana, when it was a nascent start-up, Tim has served as Chief Scientific Officer, and in 2019 was named Chief Science and Technology Officer. Since the beginning, he has led all of Mersana’s discovery efforts and is a co-inventor of all of our innovative ADC platforms and pipelines.

Prior to joining Mersana, Tim had nearly 15 years of international scientific leadership and drug discovery experience in the pharmaceutical industry. Over the course of his career at Bayer Pharmaceuticals in the US, Japan, and Germany, he contributed to the discovery of more than 15 preclinical and clinical drug candidates in the areas of oncology, asthma, inflammation, virology, obesity, and diabetes. Most notably, Tim is a co-inventor and was the discovery project leader of the pioneering anti-angiogenic kinase inhibitor Nexavar (sorafenib), approved for the treatment of renal and hepatocellular cancer. He was also involved in the discovery of Stivarga (regorafenib), approved for the treatment of metastatic colorectal cancer. While Head of Chemistry for Bayer in Japan, he initiated and oversaw the discovery and optimization of PI3K inhibitors which resulted in the approved drug Aliqopa (copanlisib), a treatment for relapsed follicular lymphoma, and while Department Head, Medicinal Chemistry in Germany, he oversaw the optimization of the HCMV anti-viral program, which resulted in the approved anti-viral drug PREVYMISTM (letermovir), licensed to Merck US. His role at Bayer prior to joining Mersana was as VP of Chemistry Research US, where he led a department of 150 scientists in the areas of medicinal, computational, process development, and analytical chemistry focused on oncology drug discovery.

Tim has published and presented widely in the fields of synthetic and medicinal chemistry, polymer-drug conjugates and ADCs, and is a co-inventor on more than 50 patents. He holds a B.Sc. (Hons.) in Chemistry and a Ph.D. in Organic Chemistry from the University of British Columbia, and was a Merck Postdoctoral Fellow at the Ohio State University in the labs of Professor Leo A. Paquette.

In his personal life, it’s a poorly kept secret that Tim is a fan of all things Japanese, from scaling Mt. Fuji to see the sunrise on his birthday, to finding the best places to eat okonomiyaki, or even to naming his beloved labradoodle Yoshi (Japanese for lucky).

What is Timothy B. Lowinger's net worth?

The estimated net worth of Timothy B. Lowinger is at least $125,286.96 as of July 1st, 2021. Dr. Lowinger owns 33,321 shares of Mersana Therapeutics stock worth more than $125,287 as of April 16th. This net worth approximation does not reflect any other investments that Dr. Lowinger may own. Additionally, Dr. Lowinger receives an annual salary of $666,300.00 as Insider at Mersana Therapeutics. Learn More about Timothy B. Lowinger's net worth.

How old is Timothy B. Lowinger?

Dr. Lowinger is currently 60 years old. There are 5 older executives and no younger executives at Mersana Therapeutics. Learn More on Timothy B. Lowinger's age.

What is Timothy B. Lowinger's salary?

As the Insider of Mersana Therapeutics, Inc., Dr. Lowinger earns $666,300.00 per year. Learn More on Timothy B. Lowinger's salary.

How do I contact Timothy B. Lowinger?

The corporate mailing address for Dr. Lowinger and other Mersana Therapeutics executives is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. Mersana Therapeutics can also be reached via phone at (617) 498-0020 and via email at [email protected]. Learn More on Timothy B. Lowinger's contact information.

Has Timothy B. Lowinger been buying or selling shares of Mersana Therapeutics?

Timothy B. Lowinger has not been actively trading shares of Mersana Therapeutics during the last ninety days. Most recently, Timothy B. Lowinger sold 4,741 shares of the business's stock in a transaction on Tuesday, January 18th. The shares were sold at an average price of $5.92, for a transaction totalling $28,066.72. Learn More on Timothy B. Lowinger's trading history.

Who are Mersana Therapeutics' active insiders?

Mersana Therapeutics' insider roster includes Lawrence Alleva (Director), Andrew Hack (Director), Timothy Lowinger (Insider), Ashish Mandelia (VP), Anna Protopapas (CEO), and Arvin Yang (Insider). Learn More on Mersana Therapeutics' active insiders.

Are insiders buying or selling shares of Mersana Therapeutics?

During the last twelve months, insiders at the sold shares 7 times. They sold a total of 54,872 shares worth more than $147,416.84. The most recent insider tranaction occured on January, 16th when Director Anna Protopapas sold 29,399 shares worth more than $79,671.29. Insiders at Mersana Therapeutics own 12.5% of the company. Learn More about insider trades at Mersana Therapeutics.

Information on this page was last updated on 1/16/2024.

Timothy B. Lowinger Insider Trading History at Mersana Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/18/2022Sell4,741$5.92$28,066.72View SEC Filing Icon  
7/19/2021Sell8,496$12.02$102,121.92View SEC Filing Icon  
7/16/2021Sell7,775$12.47$96,954.25View SEC Filing Icon  
7/1/2021Sell1,886$13.60$25,649.6033,321View SEC Filing Icon  
6/21/2021Sell2,220$13.78$30,591.6031,446View SEC Filing Icon  
5/20/2021Sell4,102$14.10$57,838.2033,319View SEC Filing Icon  
4/20/2021Sell4,102$15.91$65,262.8233,319View SEC Filing Icon  
3/22/2021Sell8,203$17.50$143,552.5033,318View SEC Filing Icon  
1/20/2021Sell8,203$21.54$176,692.6233,318View SEC Filing Icon  
12/21/2020Sell8,203$25.60$209,996.801,874View SEC Filing Icon  
11/20/2020Sell8,203$23.05$189,079.151,874View SEC Filing Icon  
10/21/2020Sell4,101$17.50$71,767.501,875View SEC Filing Icon  
9/21/2020Sell20,614$20.66$425,885.2416,160View SEC Filing Icon  
9/24/2018Sell3,500$11.63$40,705.00View SEC Filing Icon  
8/27/2018Sell3,500$13.15$46,025.00View SEC Filing Icon  
7/23/2018Sell3,500$11.06$38,710.00View SEC Filing Icon  
See Full Table

Timothy B. Lowinger Buying and Selling Activity at Mersana Therapeutics

This chart shows Timothy B Lowinger's buying and selling at Mersana Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mersana Therapeutics Company Overview

Mersana Therapeutics logo
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $3.76
Low: $3.71
High: $3.81

50 Day Range

MA: $4.50
Low: $3.59
High: $5.94

2 Week Range

Now: $3.76
Low: $0.80
High: $9.62


682,987 shs

Average Volume

2,213,186 shs

Market Capitalization

$456.09 million

P/E Ratio


Dividend Yield